Evidence map›Paper›PMID 41884844›Full record

ArticleFrontiers in immunology2026

Clinical characteristics and decreased CD4

Yan Yang, Dan Lu, Bei Wu, Lijun Wan, Xiaoyun Zhan, Alan Zhao, Pei Tan, Buyun Shi, Juan Huang, Yinghong Lu

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yan YangDepartment of Pediatric Hematology, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Dan LuDepartment of Laboratory medicine, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Bei WuDepartment of Pediatric Hematology, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Lijun WanDepartment of Pediatric Hematology, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xiaoyun ZhanDepartment of Pediatric Hematology, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Alan ZhaoDepartment of Pediatric Hematology, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Pei TanDepartment of Pediatric Hematology, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Buyun ShiDepartment of Pediatric Intensive Care Unit, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Juan Huang *Department of Pediatric Hematology, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yinghong Lu *Department of Pediatric Hematology, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Immune thrombocytopenia (ITP) exhibits distinct epidemiological characteristics in terms of age and sex distribution. In contrast to adult ITP, the clinical features and immunological mechanisms underlying pediatric ITP remain incompletely understood. Objective: To analyze the clinical characteristics, treatment response and immunological profiles of newly diagnosed pediatric ITP patients, in order to provide a reference for clinical diagnosis and treatment. Methods: This study enrolled 240 newly diagnosed pediatric ITP patients. Demographic characteristics, predisposing factors, clinical manifestations, treatment response, and prognosis were analyzed. Lymphocyte subsets were assessed by flow cytometry, and serum cytokine levels were measured using ELISA. Results: The <1 year age group constituted the largest subgroup (51.67%). Gender distribution differed significantly across the age groups ( Conclusion: Pediatric ITP demonstrates significant differences from adult ITP in age distribution, sex characteristics, and prognosis. The underlying immune dysregulation involves decreased regulatory T cells, significantly reduced levels of their specific anti-inflammatory cytokine IL-35 and concomitant expansion of CD8

Indexed as

InterleukinsPurpura, Thrombocytopenic, IdiopathicT-Lymphocytes, RegulatoryAdolescentChildChild, PreschoolCytokinesFemaleForkhead Transcription FactorsHumansInfantInterleukin-2 Receptor alpha SubunitMalePrognosisCytokinesForkhead Transcription FactorsFOXP3 protein, humanInterleukin-2 Receptor alpha Subunitinterleukin-35, humanInterleukinscytokinesdescriptive epidemiologyIL-35pediatric immune thrombocytopeniaregulatory T cells

Identifiers

PMID41884844
PMCPMC13011169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.